The Experts below are selected from a list of 33 Experts worldwide ranked by ideXlab platform
Claus G Roehrborn - One of the best experts on this subject based on the ideXlab platform.
-
alfuzosin overview of pharmacokinetics safety and efficacy of a clinically uroselective α blocker
Urology, 2001Co-Authors: Claus G RoehrbornAbstract:Abstract Efficacy and safety of alfuzosin administered as 3-times-daily and 2-times-daily formulations have been previously demonstrated in placebo-controlled studies, and these formulations have been commercially available in many countries. A once-daily formulation of alfuzosin administered through a novel prolonged-release system has been recently developed to improve the convenience of dosing and to provide optimal pharmacokinetic coverage over 24 hours. The results of 2 double-blind, placebo-controlled phase 3 studies in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia suggests that 10 mg of alfuzosin administered once daily without dose titration is superior to placebo in terms of symptom and urinary flow rate improvement. Orthostatic hypotension and First-Dose Phenomenon related to the α-blocking property were rare. The incidences of asthenia and fatigue were comparable to those seen with placebo. Ejaculatory disorders were very rare. The most frequently reported adverse event potentially related to α blockade was dizziness, which occurred in 5.0% of patients treated with 10 mg alfuzosin compared with 2.1% of patients given placebo.
-
Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Urology, 2001Co-Authors: Claus G RoehrbornAbstract:Efficacy and safety of alfuzosin administered as 3-times-daily and 2-times-daily formulations have been previously demonstrated in placebo-controlled studies, and these formulations have been commercially available in many countries. A once-daily formulation of alfuzosin administered through a novel prolonged-release system has been recently developed to improve the convenience of dosing and to provide optimal pharmacokinetic coverage over 24 hours. The results of 2 double-blind, placebo-controlled phase 3 studies in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia suggests that 10 mg of alfuzosin administered once daily without dose titration is superior to placebo in terms of symptom and urinary flow rate improvement. Orthostatic hypotension and First-Dose Phenomenon related to the alpha-blocking property were rare. The incidences of asthenia and fatigue were comparable to those seen with placebo. Ejaculatory disorders were very rare. The most frequently reported adverse event potentially related to alpha blockade was dizziness, which occurred in 5.0% of patients treated with 10 mg alfuzosin compared with 2.1% of patients given placebo.
Joséa. Colina-chourio - One of the best experts on this subject based on the ideXlab platform.
-
Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein.
The American journal of cardiology, 1991Co-Authors: María Ch. Oliveros-palacios, Nereyda Godoy-godoy, Joséa. Colina-chourioAbstract:Doxazosin, a new quinazoline-derivative postsynaptic alpha 1-adrenoceptor antagonist, was studied in this randomized, double-blind, placebo-controlled 12-week study. Its effects on blood pressure (BP), heart rate, metabolic functions and renal hormones were analyzed after administration of a single oral morning dose in a 3-phase fashion when administered to 17 patients (11 women, 6 men, 21 to 59 years) with mild to moderate uncomplicated essential hypertension. After titrating the antihypertensive effective dose biweekly from 1 to 8 mg/day and a mean end titration-point dose of 4.14 +/- 0.1 mg (mean +/- standard error of the mean) at week 8 of treatment, it was adjusted to maintain diastolic BP at levels less than or equal to 90 mm Hg for up to 12 weeks of treatment when, at a final mean dose of 4.35 +/- 0.2 mg/day, BP decreased in all patients by a mean 31 +/- 3/17 +/- 2 (supine) and 39 +/- 3/15 +/- 3 (standing) mm Hg (p less than 0.005) with no increase in heart rate and no "First-Dose Phenomenon." Neither the renin-aldosterone system nor electrolyte excretion was significantly affected. Renal function and metabolic parameters also remained unchanged. Urinary kallikrein excretion was augmented 2.47-fold (p less than 0.002). There was good tolerance; 1 patient discontinued the study because of dry nose. These results suggest that long-term monotherapy with doxazosin is an effective and safe antihypertensive agent for mild to moderate essential hypertension that stimulates urinary kallikrein excretion.
Ashish Goel - One of the best experts on this subject based on the ideXlab platform.
-
Enalapril induced idiosyncratic angioneurotic edema in a patient of renal amyloidosis
2006Co-Authors: Sanjeev Bhoi, Sanjay Verma, Vineet Gupta, Ashish GoelAbstract:Angiotensin converting enzyme inhibitors (ACEi) have been used successfully in different cardiovascular as well as metabolic disorders. Common side effects are dry cough, first dose Phenomenon, hyperkalaemia and agranulocytosis. Life threatening side effects of ACEi such as anaphylactoid reactions and angioneurotic oedema are rare and poorly recognised among emergency care providers. We report a 48-year-old male with renal amyloidosis developing angioneurotic oedema due to first dose of Enalapril.
-
Enalapril-induced Idiosyncratic Angioneurotic Oedema in a Patient with Renal Amyloidosis
2006Co-Authors: Sanjeev Bhoi, Sandeep Verma, Vishal Gupta, Ashish GoelAbstract:Angiotensin converting enzyme inhibitors (ACEi) have been used successfully in different cardiovascular as well as metabolic disorders. Common side effects are dry cough, first dose Phenomenon, hyperkalaemia and agranulocytosis. Life threatening side effects of ACEi such as anaphylactoid reactions and angioneurotic oedema are rare and poorly recognised among emergency care providers. We report a 48-year-old male with renal amyloidosis developing angioneurotic oedema due to first dose of Enalapril.
María Ch. Oliveros-palacios - One of the best experts on this subject based on the ideXlab platform.
-
Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein.
The American journal of cardiology, 1991Co-Authors: María Ch. Oliveros-palacios, Nereyda Godoy-godoy, Joséa. Colina-chourioAbstract:Doxazosin, a new quinazoline-derivative postsynaptic alpha 1-adrenoceptor antagonist, was studied in this randomized, double-blind, placebo-controlled 12-week study. Its effects on blood pressure (BP), heart rate, metabolic functions and renal hormones were analyzed after administration of a single oral morning dose in a 3-phase fashion when administered to 17 patients (11 women, 6 men, 21 to 59 years) with mild to moderate uncomplicated essential hypertension. After titrating the antihypertensive effective dose biweekly from 1 to 8 mg/day and a mean end titration-point dose of 4.14 +/- 0.1 mg (mean +/- standard error of the mean) at week 8 of treatment, it was adjusted to maintain diastolic BP at levels less than or equal to 90 mm Hg for up to 12 weeks of treatment when, at a final mean dose of 4.35 +/- 0.2 mg/day, BP decreased in all patients by a mean 31 +/- 3/17 +/- 2 (supine) and 39 +/- 3/15 +/- 3 (standing) mm Hg (p less than 0.005) with no increase in heart rate and no "First-Dose Phenomenon." Neither the renin-aldosterone system nor electrolyte excretion was significantly affected. Renal function and metabolic parameters also remained unchanged. Urinary kallikrein excretion was augmented 2.47-fold (p less than 0.002). There was good tolerance; 1 patient discontinued the study because of dry nose. These results suggest that long-term monotherapy with doxazosin is an effective and safe antihypertensive agent for mild to moderate essential hypertension that stimulates urinary kallikrein excretion.
Yung Tai Chen - One of the best experts on this subject based on the ideXlab platform.
-
Effectiveness of α1-Adrenergic Blockers in Boys with Low Urinary Flow Rate and Urinary Incontinence
Journal of the Formosan Medical Association = Taiwan yi zhi, 2003Co-Authors: Stephen Shei-dei Yang, Chung Cheng Wang, Yung Tai ChenAbstract:Background and Purpose: Although α blockers have been shown to be effective in treating various types of neuropathic voiding dysfunction in children, the effectiveness of α1 blockers in treating neurologically intact children with voiding dysfunction remains unclear. We investigated the effectiveness of treatment with α1-adrenergic blockade in boys with low uroflow rate and urinary incontinence. Methods: The α1 blocker doxazosin (0.5 to 1.0 mg daily) was administered to 16 boys (mean age, 8.9 ± 3.4 years) with maximum uroflow rate (Qmax) ＜ 15 mL/s and urinary incontinence. Uroflowmetry and postvoid residual volumes were checked before and 4 weeks after doxazosin treatment. After discontinuation of doxazosin for 2 weeks, videourodynamics and cystoscopy were done in 12 of the 16 boys. Improvement of uroflow was arbitrarily defined as an increase of Qmax ≥ 2.5 mL/s. Complete improvement of incontinence was defined as ＞ 90% and partial improvement as 50 to 90% reduction of incontinence episodes. Successful treatment was defined as improvement in uroflow and partial or complete improvement of urinary incontinence. Blood pressure, First-Dose Phenomenon, and adverse effects were monitored at each visit. Results: Mean medication and follow-up periods were 24.5 weeks and 33.1 weeks, respectively. Improvement of uroflow was noted in 10 patients (63%). Qmax increased from 12.3±1.3 mL/s to 16.3 ± 4.1 mL/s (p=0.001).Complete and partial improvement of incontinence was noted in 7 and 3 patients, respectively. The mean number of wet nights per week decreased from 4.9 ± 2.3 to 2.2 ± 2.5 (p ＜ 0.001). Successful treatment was noted in 8 boys (50%), including 3 of 5 boys with primary bladder neck obstruction, 3 of 4 boys with dysfunctional voiding, and 2 of 4 boys with neuropathic voiding dysfunction of unclassified etiology. There were no significant adverse effects. Decreases of systolic and diastolic blood pressure were negligible. Conclusion: α1 Blockade is effective in the treatment of boys with low uroflow rate and incontinence.